Nickel, Marius K. and Nickel, Cerstin and Muehlbacher, M. and Leiberich, Peter K. and Kaplan, Pe and Lahmann, Claas and Tritt, Karin and Krawczyk, J. and Kettler, C. and Egger, C. and Rother, W.K. and Loew, Thomas H. (2005) Influence of topiramate on olanzapine-related adiposity in women - A random, double-blind, placebo-controlled study. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 25 (3). pp. 211-217. ISSN 0271-0749,
Full text not available from this repository. (Request a copy)Abstract
The aim of this study was to compare the efficacy of topiramate versus a placebo in the treatment of adiposity in women undergoing olanzapine therapy. We also assessed changes health-related quality of life, the patient's actual state of health, and psychologic impairments. The 10-week, random, double-blind, placebo-controlled study included 43 women who had been treated with olanzapine (mean dose 7.8 +/- 3.6 in the topiramate group and 7.2 +/- 3.1 in the placebo group) and had gained weight as a side effect. The subjects were randomly assigned to topiramate (n = 25) or a placebo (n = 18). Primary outcome measures were weight checks and self-reported changes on the scales of the SF-36 Health Survey, Bf-S Scale of Well-Being, and the Adjective Checklist EWL-60-S. Weight loss was observed and was significantly more pronounced in the topiramate-treated group (difference in weight loss between the 2 groups: 5.6 kg, 95% Cl = -8.5, -3.0, P < 0.001). In comparison with the placebo group, significant changes on 7 (7/8) scales of SF-36 Health Survey (all P < 0.001), on all 6 scales of the EWL-60-S, and on the Bf-S were observed in the topiramate-treated subjects after 10 weeks. All patients tolerated topiramate well. Topiramate appears to be a safe and effective agent in the treatment of weight gain that occurred during olanzapine treatment. Significantly positive changes in health-related quality of life, the patient's actual state of health, and psychologic impairments were observed.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | INDUCED WEIGHT-GAIN; ATYPICAL ANTIPSYCHOTICS; SCHIZOPHRENIA; ZIPRASIDONE; DISORDER; ORLISTAT; OBESITY; LEPTIN; RISKS; COSTS; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Psychosomatische Medizin |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 11 May 2021 08:13 |
| Last Modified: | 11 May 2021 08:13 |
| URI: | https://pred.uni-regensburg.de/id/eprint/36068 |
Actions (login required)
 |
View Item |
